Data collected between May 4 and May 9, 2026 through Spherix Global Insights’ Launch Dynamix™ service suggest Bristol Myers Squibb’s Sotyktu (deucravacitinib) is beginning to gain traction in ...
UCB (UCBJY) announced on Tuesday that its biologic medicine Bimzelx outperformed AbbVie’s (ABBV) immunology therapy Skyrizi ...
UCB has announced new week 16 results from the phase 3 BE BOLD trial showing that bimekizumab delivered superior joint ...
Patients with active psoriatic arthritis who have an inadequate response to TNF inhibitors, mainly those with elevated ...
Arthritis can limit daily activities, but the Aging Untold experts say there are effective ways to manage symptoms and ...
Everyday Health on MSN
Psoriatic Arthritis: What Defines Minimal Disease Activity?
This measure of how well controlled your psoriatic arthritis is can be used to guide treatment decisions.
Combination therapy with multiple biologics may be on the horizon for patients with psoriatic arthritis, according to a ...
Autoimmune and autoinflammatory arthritis are often called "invisible illnesses" because many patients may appear healthy on ...
A comparative analysis identifies the top IL-23 inhibitors that were least likely to be associated with the development of ...
A new study has found that biologic class and treatment sequencing influences psoriatic arthritis risk in patients with ...
If you have psoriatic arthritis (PsA), you may be familiar with sore fingers, stiff wrists, and the frustration of struggling with formerly simple tasks like buttoning a shirt or chopping vegetables.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results